New York | A monoclonal antibody cocktail developed by the drug-maker Regeneron offered strong protection against COVID-19 when given to people living with someone infected with the coronavirus, according to clinical trial results announced on Monday.

The drug, if authorised, could offer another line of defence against the disease for people who are not protected by vaccination.